8-K: Profound Medical Expands TULSA-PRO to ANZ Market

Profound Medical Corp. announced an exclusive distribution and supply agreement with Getz Healthcare to bring its TULSA-PRO system to Australia and New Zealand.

Summary

• Profound Medical Corp. has entered into an exclusive distribution and supply agreement with Getz Healthcare for its TULSA-PRO system in Australia and New Zealand.
• TULSA-PRO is an AI-powered, MRI-guided, incision-free therapy designed for the ablation of diseased tissue, primarily focused on prostate care.
• The system enables real-time MRI thermography and autonomous temperature control, allowing physicians to precisely ablate prostate tissue while protecting surrounding structures.
• TULSA-PRO is applicable across the entire prostate disease spectrum, including low-, intermediate-, or high-risk prostate cancer, benign prostatic hyperplasia (BPH), hybrid patients, and salvage therapy for radio-recurrent localized prostate cancer.
• Getz Healthcare is a leading distributor of medical devices, equipment, and consumables in the Asia Pacific region, with over 110 years of operation and a network of 23 offices serving over 7,500 customers.
• Profound Medical's commercial strategy includes deploying its direct sales team in North America and partnering with strategic distribution partners for other global markets.

Sentiment

Score: 8

Explanation: The announcement of an exclusive distribution agreement with a reputable partner in a significant new market for a key product is a strong positive development for Profound Medical's growth strategy and market penetration, indicating favorable prospects.

Positives

• Secured an exclusive distribution and supply agreement for the TULSA-PRO system in the significant markets of Australia and New Zealand.
• Partnered with Getz Healthcare, a well-established and leading medical device distributor in the Asia Pacific region, providing strong market access and local expertise.
• Addresses prostate cancer, which is the most commonly diagnosed cancer in men in Australasia, indicating a substantial market opportunity for TULSA-PRO.
• The TULSA-PRO system offers a minimally invasive, incisionand radiation-free treatment that preserves urinary continence and sexual function, requires no hospital stay, and allows for quick patient recovery.
• Management is actively pursuing opportunities to expand the strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific.

Negatives

• No specific financial terms, revenue projections, or sales targets related to the distribution agreement were disclosed, making it difficult to quantify the immediate financial impact.
• Reliance on a third-party distributor for market penetration outside North America introduces potential dependencies and risks related to partner performance and market execution.

Risks

• Risks inherent in the medical device industry, including challenges related to regulatory approvals and reimbursement policies.
• General economic factors and conditions in the equity markets could impact company performance and investor sentiment.
• Risks associated with growth and competition within the medical device sector.
• The efficacy of Profound's technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment, and osteoid osteoma may not meet expectations.
• The extent and timing of TULSA-PRO system sales from the qualified sales pipeline may differ from projections.
• Future revenues may not align with current expectations.
• The success of Profound's commercialization strategy and activities for TULSA-PRO is subject to various uncertainties.

Future Outlook

Profound Medical is actively pursuing opportunities to expand its strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific. The company's commercialization strategy involves deploying its direct sales team in North America while partnering with select strategic distribution partners to support business potential and customer base in other parts of the world.

Management Comments

• "Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand. The TULSA-PRO system strengthens our commitment to deliver innovative, clinically proven technologies that improve patient outcomes and further advances our position in prostate cancer surgery and minimally invasive therapies." Derek Foltin, Getz Healthcare ANZ Managing Director.
• "Like in many other regions around the globe, prostate cancer is the most commonly diagnosed cancer in men in Australasia. We are excited to gain access to this significant market for TULSA-PRO. Beyond Australia and New Zealand, we are actively pursuing other potential opportunities to expand our strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific." Arun Menawat, Profound's CEO and Chairman.

Industry Context

This agreement positions Profound Medical to capitalize on the growing demand for minimally invasive prostate care solutions in the Asia Pacific region. The partnership with a well-established regional distributor like Getz Healthcare is a common and effective strategy for medical device companies seeking to expand internationally without incurring the full costs of direct market entry, aligning with broader industry trends of strategic alliances for global reach and market penetration.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and long-term value creation due to expanded market access and strategic partnership.
• Patients (Australia & New Zealand): Gaining access to an innovative, minimally invasive, and precise treatment option for prostate conditions, potentially improving outcomes and quality of life.
• Healthcare Providers (Australia & New Zealand): New advanced technology becomes available to enhance their treatment offerings for prostate cancer and BPH.
• Employees (Profound Medical): Positive impact on company growth and stability, potentially leading to new opportunities and job security.
• Getz Healthcare: Strengthens its portfolio of innovative medical technologies and enhances its market position in prostate care within the Asia Pacific region.

Next Steps

• Getz Healthcare will commence the distribution and supply of the TULSA-PRO system in Australia and New Zealand.
• Profound Medical will continue to pursue potential opportunities to expand its strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific.
• Profound Medical will continue to deploy its direct sales team in North America to support its business.

Key Dates

Recommendation

The exclusive distribution agreement with Getz Healthcare for the TULSA-PRO system in Australia and New Zealand represents a significant strategic win for Profound Medical. This partnership opens a substantial new market for a key product, leveraging an established and reputable distributor in a region with high prostate cancer incidence. While specific financial terms are not disclosed, the expansion into a new, large market with a strong partner is a clear catalyst for future revenue growth and market penetration, making the stock an attractive 'buy' for long-term investors.

Keywords

Profound Medical, TULSA-PRO, Getz Healthcare, Prostate Cancer, BPH, Medical Device, MRI-guided, Ultrasound Therapy, Australia, New Zealand, Distribution Agreement, Healthcare Technology, Ablation Therapy